LUMA Study

LUMA: Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease

The purpose of this study is to test an investigational drug called BIIB122 to see if it may slow the progression of PD.

Key Criteria:

• Are 30 to 80 years old
• Were diagnosed with Parkinson’s disease within the last 2 years and were at least 30 years old when you were diagnosed
• Willing to participate in a study for up to 146 weeks

For more information, contact Hannah Babcock at 617-667-9890 or hbabcock@bidmc.harvard.edu